Effects of Leuprorelin acetate sustained-release microspheres for injection combined with Bicalutamide capsules in treatment of elderly patients with prostate cancer
Objective:To observe effects of Leuprorelin acetate sustained-release microspheres for injection combined with Bicalutamide capsules in treatment of elderly patients with prostate cancer.Methods:A prospective study was conducted on 92 elderly patients with prostate cancer admitted to this hospital from February 2021 to January 2023.According to the random number table method,they were divided into observation group and control group,46 cases in each group.The control group was treated with Bicalutamide capsules,while the observation group was treated with Leuprorelin acetate sustained-release microspheres for injection on the basis of that of the control group.The total effective rate,the laboratory indexes[prostate-specific antigen(PSA),free prostate-specific antigen(f-PSA),vascular endothelial growth factor(VEGF),serum transforming growth factor-α(TGF-α)and transforming growth factor-β1(TGF-β1)]levels and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 73.91%,which was significantly higher than 52.17%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of serum PSA,f-PSA,VEGF,TGF-α and TGF-β1 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Leuprorelin acetate sustained-release microspheres for injection combined with Bicalutamide capsules in the treatment of the elderly patients with prostate cancer can improve the total effective rate of treatment and reduce the levels of laboratory indexes.Moreover,it is superior to single Bicalutamide capsule treatment.
维普
万方数据
